TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33669675

Group type: EXPERIMENTAL
Intervention: Body Composition (BC) parameters measured by dual-energy X-ray absorptiometry
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Training volume and pattern assessed via an author-developed questionnaire
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Injury status assessed via a modified questionnaire on overuse injuries
Number of subjects: 17
Study: 33669715

Group type: EXPERIMENTAL
Intervention: Music-based rhythmic auditory stimulation (RAS) in combination with conventional physiotherapy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 55
Study: 33670796

Group type: EXPERIMENTAL
Intervention: Cigarette use
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: E-cigarette use
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Health literacy
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Sociodemographic factors
Number of subjects: 322
Study: 33671555

Group type: EXPERIMENTAL
Intervention: IO103 vaccine with Montanide adjuvant
Number of subjects: 10
Study: 33671691

Group type: EXPERIMENTAL
Intervention: Probiotic product (1 capsule/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33673615

Group type: EXPERIMENTAL
Intervention: V-V ECMO
Number of subjects: 127
Study: 33673868

Group type: EXPERIMENTAL
Intervention: Wearable patch for remote monitoring of vital signs (heart rate, respiratory rate, temperature) during stay in hotel quarantine.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Central monitoring hub for nursing staff to view notifications of deterioration.
Number of subjects: 0
Study: 33673873

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted pterygium surgery (FLAPS) with conjunctival autograft (CAG)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted pterygium surgery (FLAPS) with ultrathin CAG (mean thickness of 74.5 ± 9.8 μm)
Number of subjects: 29
Study: 33673929

Group type: EXPERIMENTAL
Intervention: Lenzilumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33674274

Group type: EXPERIMENTAL
Intervention: Decitabine (10 mg/day, days 1-5) plus camrelizumab (200 mg, day 8), every 3 weeks
Number of subjects: 51
Study: 33674354

Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open surgical repair
Number of subjects: 0
Study: 33674398

Group type: EXPERIMENTAL
Intervention: Gastrin-releasing peptide receptor-targeting PET
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PSMA-targeted PET
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard imaging techniques
Number of subjects: 50
Study: 33674419

Group type: EXPERIMENTAL
Intervention: Early rheumatoid arthritis (ERA) group
Number of subjects: 56

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 56
Study: 33674856

Group type: EXPERIMENTAL
Intervention: Facebook group intervention to reduce barriers to evidence-based smoking cessation treatment
Number of subjects: 70
Study: 33675034

Group type: EXPERIMENTAL
Intervention: Telehealth intervention
Number of subjects: 0
Study: 33675179

Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin 2.4 mg/kg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin 2.7 mg/kg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin (both doses)
Number of subjects: 9
Study: 33675184

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT) with TI-CE regimen, including two cycles of paclitaxel and ifosfamide followed by three cycles of HD carboplatin plus etoposide, with carboplatin dose adapted based on clearance to reach a target AUC of 24 mg.min/mL per cycle.
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT) with TI-CE regimen.
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT) with TI-CE regimen for high- and very high-risk patients.
Number of subjects: 89
Study: 33675321

Group type: EXPERIMENTAL
Intervention: Irish calculator (IC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified definition of DGF (excluding those with single dialysis in the first 24 h posttransplant)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recipient cardiovascular disease
Number of subjects: 0
Study: 33675592

Group type: EXPERIMENTAL
Intervention: Aktiia Bracelet
Number of subjects: 86
Study: 33675635

Group type: EXPERIMENTAL
Intervention: Decreased physical activity (reported by 53% of participants)
Number of subjects: 37252

Group type: EXPERIMENTAL
Intervention: Increased sedentary time (reported by 63%)
Number of subjects: 37252

Group type: EXPERIMENTAL
Intervention: Increased snacking
Number of subjects: 37252

Group type: EXPERIMENTAL
Intervention: Decreased consumption of fresh food (especially fruit and fish)
Number of subjects: 37252

Group type: EXPERIMENTAL
Intervention: Increased consumption of sweets, cookies, and cakes
Number of subjects: 37252

Group type: EXPERIMENTAL
Intervention: Increased home cooking (reported by 40%)
Number of subjects: 37252

Group type: EXPERIMENTAL
Intervention: Increased physical activity (reported by 19%)
Number of subjects: 37252

Group type: EXPERIMENTAL
Intervention: Weight gain (35% of participants, mean weight gain 1.8 kg ± SD 1.3 kg)
Number of subjects: 37252

Group type: EXPERIMENTAL
Intervention: Weight loss (23% of participants, mean weight loss 2 kg ± SD 1.4 kg)
Number of subjects: 37252
Study: 33675642

Group type: EXPERIMENTAL
Intervention: Intraoperative high-frequency ultrasound and transit-time flow measurement (TTFM) in CABG procedures
Number of subjects: 1016

Group type: COMPARATOR
Intervention: Normal renal function
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Post-protamine graft TTFM parameters
Number of subjects: 1016
Study: 33676017

Group type: EXPERIMENTAL
Intervention: Crizotinib (250 mg twice daily)
Number of subjects: 38
Study: 33676165

Group type: EXPERIMENTAL
Intervention: Pregnant women with Ph-negative ALL
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-pregnant women with Ph-negative ALL
Number of subjects: 15
Study: 33676426

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 155
Study: 33676431

Group type: EXPERIMENTAL
Intervention: Algorithm Phase (AP)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Usual Care Phase (UCP)
Number of subjects: 162
Study: 33676455

Group type: EXPERIMENTAL
Intervention: Music intervention (preferred genre, wireless headphones for up to 30 minutes)
Number of subjects: 172
Study: 33676547

Group type: EXPERIMENTAL
Intervention: Palbociclib plus fulvestrant
Number of subjects: 61
Study: 33676628

Group type: EXPERIMENTAL
Intervention: Pirtobrutinib 200 mg daily
Number of subjects: 323
Study: 33677480

Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1) alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (anti-PD-1 and anti-CTLA-4) combination therapy
Number of subjects: 40
Study: 33677504

Group type: COMPARATOR
Intervention: Congenital adrenal hyperplasia (CAH) patients
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Increased mineralocorticoid dose during childhood
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Suppressed androstenedione during adulthood
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Suppressed testosterone during adulthood
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Elevated 17-hydroxyprogesterone in children
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Maternal obesity
Number of subjects: 57
Study: 33677530

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33677532

Group type: EXPERIMENTAL
Intervention: AFB1-lysine adduct concentrations
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Serum aflatoxin concentrations
Number of subjects: 1675
Study: 33677553

Group type: EXPERIMENTAL
Intervention: Chemical renal denervation (RDN) using Peregrine System Infusion Catheter, Ablative Solutions (n = 4; 2F:2M)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Chemical renal denervation (RDN)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control renal angiography (n = 3; 2F:1M)
Number of subjects: 7
Study: 33677615

Group type: EXPERIMENTAL
Intervention: UGN-101 (mitomycin-containing reverse thermal gel)
Number of subjects: 6
Study: 33677695

Group type: COMPARATOR
Intervention: Sedation
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Non-sedation
Number of subjects: 79
Study: 33677832

Group type: COMPARATOR
Intervention: DBT-A
Number of subjects: 2280

Group type: COMPARATOR
Intervention: Individual CBT-based psychotherapy
Number of subjects: 2280

Group type: COMPARATOR
Intervention: Mentalisation based therapy for adolescents (MBT-A)
Number of subjects: 2280

Group type: COMPARATOR
Intervention: Family therapy
Number of subjects: 2280

Group type: COMPARATOR
Intervention: Compliance enhancement approaches
Number of subjects: 2280

Group type: COMPARATOR
Intervention: Group-based psychotherapy
Number of subjects: 2280

Group type: COMPARATOR
Intervention: Remote contact intervention (emergency cards)
Number of subjects: 2280

Group type: COMPARATOR
Intervention: Therapeutic assessment
Number of subjects: 2280
Study: 33677986

Group type: EXPERIMENTAL
Intervention: ART experienced individuals
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Tenofovir treatment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 3TC treatment
Number of subjects: 44
Study: 33678938

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) patients
Number of subjects: 6217
Study: 33679057

Group type: EXPERIMENTAL
Intervention: 1% end-tidal sevoflurane
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 2% end-tidal sevoflurane
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Postoperative RVOT gradient
Number of subjects: 21
Study: 33679255

Group type: EXPERIMENTAL
Intervention: Spontaneous Breathing (SB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Airway Pressure Release Ventilation (APRV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled Ventilation
Number of subjects: 0
Study: 33679374

Group type: EXPERIMENTAL
Intervention: Management modalities for brain AVMs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33679432

Group type: EXPERIMENTAL
Intervention: Flicker-light induced retinal vessel dilatation (FID)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Blood pressure-induced myogenic constriction
Number of subjects: 18
Study: 33679447

Group type: EXPERIMENTAL
Intervention: Light-load PRT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Heavy-load PRT
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-exercise
Number of subjects: 30
Study: 33679469

Group type: EXPERIMENTAL
Intervention: Homeostatic sleep pressure buildup, specific details not available
Number of subjects: 0
Study: 33679478

Group type: EXPERIMENTAL
Intervention: Internet-Administered Emotional Awareness and Expression Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33679529

Group type: EXPERIMENTAL
Intervention: School-based active lifestyle intervention including teacher training, environmental improvements, and educational strategies.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 0
Study: 33679572

Group type: EXPERIMENTAL
Intervention: Real 10 Hz rTMS stimulation with the H2-coil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham rTMS stimulation
Number of subjects: 30
Study: 33680117

Group type: EXPERIMENTAL
Intervention: Danon disease patients (n=7)
Number of subjects: 7
Study: 33680364

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33681244

Group type: EXPERIMENTAL
Intervention: Improved use of chewing gum during capsule endoscopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard procedure without chewing gum)
Number of subjects: 0
Study: 33681273

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term treatments (three different types)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33681680

Group type: EXPERIMENTAL
Intervention: Cenicriviroc (CVC)
Number of subjects: 24
Study: 33681685

Group type: EXPERIMENTAL
Intervention: Systemic therapy
Number of subjects: 1841
Study: 33681744

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam (5 mg)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine
Number of subjects: 206

Group type: COMPARATOR
Intervention: Intramuscular haloperidol
Number of subjects: 206
Study: 33681747

Group type: EXPERIMENTAL
Intervention: Melatonin (20 mg nightly for one year)
Number of subjects: 709

Group type: COMPARATOR
Intervention: Placebo (nightly for one year)
Number of subjects: 709
Study: 33681776

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC) - 3 cycles, BP cuff inflated to 30 mm Hg above systolic BP
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sham intervention - BP cuff inflated to 30 mm Hg below diastolic BP
Number of subjects: 75
Study: 33682355

Group type: EXPERIMENTAL
Intervention: HR-HPV (DH3)
Number of subjects: 5171

Group type: COMPARATOR
Intervention: Cytology test
Number of subjects: 5171

Group type: EXPERIMENTAL
Intervention: HPV16/18 viral load
Number of subjects: 5171

Group type: EXPERIMENTAL
Intervention: HPV16/18 and other 12 HR-HPV
Number of subjects: 5171
Study: 33682430

Group type: EXPERIMENTAL
Intervention: Somryst™ (digital therapeutic for insomnia)
Number of subjects: 350
Study: 33682447

Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin combined with novel agents (GSK3174998, feladilimab, nirogacestat, dostarlimab)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Belantamab mafodotin monotherapy
Number of subjects: 0
Study: 33682527

Group type: EXPERIMENTAL
Intervention: Opioid receptor antagonists, specific dosage and duration not mentioned
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33682678

Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg subcutaneously once daily for 10 days
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard-of-care comparators
Number of subjects: 130
Study: 33682716

Group type: EXPERIMENTAL
Intervention: Positive baseline amyloid PET
Number of subjects: 25

Group type: COMPARATOR
Intervention: Negative baseline amyloid PET
Number of subjects: 25
Study: 33683342

Group type: EXPERIMENTAL
Intervention: NLRP3 inflammasome stimulation in peripheral myeloid cells from COVID-19 patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NLRP3 inflammasome stimulation in peripheral myeloid cells from recovered COVID-19 patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy donors (control group)
Number of subjects: 0
Study: 33683482

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel and cisplatin
Number of subjects: 80

Group type: COMPARATOR
Intervention: nab-paclitaxel monotherapy
Number of subjects: 80
Study: 33683582

Group type: COMPARATOR
Intervention: Escitalopram monotherapy (n = 82, ESC-CONT)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Adjunctive Aripiprazole (n = 88, ESC-ARI)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Healthy participants (n = 112)
Number of subjects: 209
Study: 33683917

Group type: EXPERIMENTAL
Intervention: Umbralisib 800 mg orally once daily until disease progression, unacceptable toxicity, or study withdrawal
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Umbralisib 800 mg orally once daily
Number of subjects: 208
Study: 33684111

Group type: EXPERIMENTAL
Intervention: Combined water and sanitation intervention
Number of subjects: 471

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 471

Group type: COMPARATOR
Intervention: MPO (biomarker)
Number of subjects: 471

Group type: COMPARATOR
Intervention: NEO (biomarker)
Number of subjects: 471

Group type: COMPARATOR
Intervention: AAT (biomarker)
Number of subjects: 471
Study: 33684160

Group type: EXPERIMENTAL
Intervention: GSK1070806 (3 mg/kg intravenous)
Number of subjects: 7
Study: 33684371

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33684377

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin (SCIG) at 0.1 g/kg/week for up to 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 20
Study: 33684474

Group type: EXPERIMENTAL
Intervention: Zenith t-Branch multibranched thoracoabdominal stent-graft
Number of subjects: 80
Study: 33684930

Group type: EXPERIMENTAL
Intervention: Diarrheal samples with low Megasphaera abundance
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pre-infection microbiome composition
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Microbiome composition broadly
Number of subjects: 72
Study: 33685522

Group type: EXPERIMENTAL
Intervention: MANTRa therapy (24 to 34 individual weekly sessions)
Number of subjects: 100

Group type: COMPARATOR
Intervention: TAU (treatment as usual, weekly sessions)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MANTRa therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 100
Study: 33685975

Group type: EXPERIMENTAL
Intervention: Daratumumab
Number of subjects: 11
Study: 33686413

Group type: EXPERIMENTAL
Intervention: Individualised luteal phase support (iLPS) through daily subcutaneous P4 injections (Psc) started the day prior to FET.
Number of subjects: 574
Study: 33686452

Group type: EXPERIMENTAL
Intervention: Crenigacestat (LY3039478) in combination with LY3023414
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Crenigacestat (LY3039478) in combination with abemaciclib
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Crenigacestat (LY3039478) in combination with taladegib
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Crenigacestat (LY3039478)
Number of subjects: 63
Study: 33686472

Group type: EXPERIMENTAL
Intervention: COMMANDER-HF
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: EPHESUS
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: EXAMINE
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: All trials
Number of subjects: 3
Study: 33686542

Group type: EXPERIMENTAL
Intervention: Functional measures including maximal cardiopulmonary exercise testing (CPET)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Veterans Specific Activity Questionnaire (VSAQ)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 6-min walk test (6MWT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pulmonary function tests
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Body composition determined by dual X-ray absorptiometry
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Sit-to-stand test (STS)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Upper and lower body strength measures
Number of subjects: 39
Study: 33686559

Group type: EXPERIMENTAL
Intervention: ECMO treatment
Number of subjects: 30
Study: 33686573

Group type: EXPERIMENTAL
Intervention: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
Number of subjects: 86
Study: 33686574

Group type: EXPERIMENTAL
Intervention: Home-based screening using community health workers (CHWs)
Number of subjects: 60
Study: 33686631

Group type: EXPERIMENTAL
Intervention: Talazoparib (1 mg/day for mild renal impairment, 0.75 mg/day for moderate renal impairment, 0.5 mg/day for severe renal impairment)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Talazoparib (0.5 mg/day for severe renal impairment)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal renal function (control group)
Number of subjects: 34
Study: 33686914

Group type: EXPERIMENTAL
Intervention: DENV 2016-2017 strains
Number of subjects: 0

Group type: COMPARATOR
Intervention: DENV 2013-2014 strains
Number of subjects: 0
Study: 33687069

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 11232

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 11232

Group type: COMPARATOR
Intervention: Hydroxychloroquine
Number of subjects: 11232

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 11232
Study: 33687163

Group type: EXPERIMENTAL
Intervention: Metformin (1500 mg per day)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 33687554

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment (NSPT)
Number of subjects: 43
Study: 33687667

Group type: EXPERIMENTAL
Intervention: Automated method based on shape analysis using Gaussian support vector machine (G-SVM) for ECoG electrodes recognition.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Automated method based on shape analysis using Gaussian support vector machine (G-SVM) for simultaneous recognition of depth and ECoG electrodes.
Number of subjects: 24
Study: 33687687

Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection (RCI; Acthar) 80 U subcutaneously every other day through week 4, then twice weekly through week 24
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection (RCI; Acthar)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33687761

Group type: EXPERIMENTAL
Intervention: House dust mite sensitization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eczema
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wheeze
Number of subjects: 0
Study: 33687786

Group type: EXPERIMENTAL
Intervention: PRO-C11-511
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: PRO-C11-511 (>75th percentile)
Number of subjects: 39
Study: 33688022

Group type: EXPERIMENTAL
Intervention: Galunisertib 150 mg two times per day co-administered with durvalumab 1500 mg Q4W
Number of subjects: 32
Study: 33688091

Group type: EXPERIMENTAL
Intervention: Chronic lung disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Binge drinking
Number of subjects: 0

Group type: COMPARATOR
Intervention: No chronic lung disease
Number of subjects: 0
Study: 33688228

Group type: EXPERIMENTAL
Intervention: Orlistat (120mg three times daily) and Phentermine (37.5mg once daily)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo (three times daily) and Phentermine (37.5mg once daily)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Orlistat/phentermine
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo/phentermine
Number of subjects: 114

Group type: COMPARATOR
Intervention: Phentermine alone
Number of subjects: 114
Study: 33688276

Group type: EXPERIMENTAL
Intervention: Transcervical fibroid ablation (TFA) using the Sonata system
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Transcervical fibroid ablation (TFA)
Number of subjects: 500
Study: 33688615

Group type: EXPERIMENTAL
Intervention: Combined physical and cognitive training for 10 weeks
Number of subjects: 12